Onychomycosis
Conditions
Keywords
Onychomycosis, Nail fungus, Tinea Unguium
Brief summary
The purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel. Iontophoretic delivery involves the use of a small electric charge to deliver drug across skin and nails.
Interventions
DRUGTerbinafine HCl
4% w/w terbinafine HCL gel, single dose,
Sponsors
Nitric BioTherapeutics, Inc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Positive KOH * 25-75% involvement of the visible nail. * Nail plate must be \< 3 mm thick. * Must have signed informed consent. * Must agree to avoid any type of pedicure or application of any nail polish product or nail cosmetic to the toenails after the screening visit until Day 28. * Female subjects of childbearing potential must agree to take measures to avoid pregnancy until the day after Day 28 * Must agree to avoid the use of oral antifungals or topical terbinafine anywhere on the body until the day after Day 28. Topical antifungals other than terbinafine can be used on the body other than the feet after Day 0.
Exclusion criteria
* Presence of proximal subungual onychomycosis or white superficial onychomycosis * Fungal involvement of a majority of the lunula * Subjects with psoriasis, eczema, or other abnormalities that could result in a clinically abnormal nail * Presence of dermatophytoma or onychomycotic spikes or exclusively lateral groove involvement * Traumatized or dystrophic target great toenail. * Known diabetics * Subjects with peripheral vascular disease * Subjects who are immunosuppressed (chronic corticosteroid therapy, solid organ or bone marrow transplantation, cytotoxic chemotherapy within the previous 12 months (or planned within the next 12 months), or HIV infection. * Use of systemic corticosteroids within 30 days preceding Day 0 * Use of topical antifungals on the feet in the preceding 30 days of Day 0 through Day 28 * Use of topical terbinafine in the 30 days prior to treatment through Day 28 * Use of systemic antifungals in the preceding 120 days of Day 0 through Day 28 * Use of any investigational drug(s) within 30 days (120 days for systemic antifungals) preceding Day 0 through Day 28 * Has previously participated in this study * Is pregnant or is a nursing mother * Women of of child bearing potential who are not using an adequate form of contraception (or abstinence) * Subjects with pacemakers/automatic implantable cardioverter/defibrillators * Subjects with an implantable electronic device. * Subjects with a bleeding disorder or who are using warfarin or any other blood coagulation modulator including aspirin in the 14 days prior to treatment through Day 28
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of terbinafine in the nail bed (ng/mg) | Day 28 |
| Plasma terbinafine levels (ng/ml) | Day 28 |
Secondary
| Measure | Time frame |
|---|---|
| Number of treatment emergent adverse events (AEs)& Serious Adverse Events (SAEs) | 60 days |
Countries
United States
Outcome results
None listed